Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
PARP inhibitors are orally administered antineoplastic agents that affect the homologous recombination (HR) repair pathway, and are approved by the FDA for the treatment of ovarian, breast, pancreatic, and prostate cancers. This report presents a case of recurrent endometrial carcinoma occurring in a woman with a germline pathogenic PALB2 whole-exon deletion. This uncommon finding in a patient with endometrial carcinoma provided the opportunity to use a management strategy of PARP inhibition with olaparib, resulting in a prolonged response to treatment; however, disease progression eventually occurred. Further studies are required to elucidate the mechanisms underlying resistance to PARP inhibition, and the potential future treatment options in this setting. Current recommendations for risk management of female carriers of PALB2 variants focus on breast and ovarian cancer risk. This case raises the additional question of a potential role for risk-reducing hysterectomy in female carriers of PALB2 variants.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.6004/jnccn.2021.7067 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prevalence of germline pathogenic variants in 779 patients with metastatic prostate cancer.
BJU Int
September 2025
Division Laboratories, Pharmacy and Biomedical Genetics, Department of Genetics, University Medical Center Utrecht, Utrecht, The Netherlands.
Objective: To assess the prevalence of germline pathogenic variants (gPVs) in genes associated with female breast cancer in Dutch patients with metastatic prostate cancer (mPCa).
Patients And Methods: In this prospective multicentre cohort study (n = 15 centres), germline genetic testing of the genes BRCA1, BRCA2, ATM, CHEK2 and PALB2 was offered to patients with mPCa. We assessed the prevalence of gPVs and compared it to a reference population of 16 823 individuals who underwent genetic testing for non-oncological conditions.
Impact of Incidental Germline BRCA1/2 and PALB2 Alterations on EGFR Monotherapy Real-World Outcomes for Patients With Advanced Non-Small-Cell Lung Cancer.
Clin Lung Cancer
August 2025
Department of Medicine, Division of Hematology/Oncology, Northwestern University, Chicago, IL; Tempus AI, Tempus, Chicago, IL.
Introduction: Several studies have sought to determine the prevalence of BRCA1/BRCA2 in patient populations, but few have studied impacts of such alterations on patient outcomes beyond breast, ovarian, prostate and pancreatic cancers. This study assessed patient outcomes from a large real-world evidence (RWE) database for patients with EGFR-mutated advanced non-small-cell lung cancer (aNSCLC) who also had incidental pathogenic germline variants (iPGVs) in BRCA1, BRCA2 or PALB2 identified by a well-validated liquid biopsy.
Materials And Methods: Outcomes from patients included in GuardantINFORM, a RWE database, from Oct 2018-June 2024 with a diagnosis of aNSCLC and an incidental pathogenic germline variant (iPGV) in BRCA1/2 or PALB2 included in OncoKB treated with EGFR monotherapy (gBRCA/PALB2+) were matched in 1:5 using coarsened exact matching to a control cohort without iPGVs (control).
Established Cancer Predisposition Genes in Single and Multiple Cancer Diagnoses.
JAMA Oncol
August 2025
Department of Medicine and the Duke Cancer Institute, Duke University School of Medicine, Durham, North Carolina.
Importance: Much of the understanding of cancer risk associated with rare pathogenic variants (RPVs) is derived from family-based studies or clinically ascertained samples, which may be limited by ascertainment and selection bias.
Objective: To quantify associations between RPVs in previously implicated cancer predisposition genes and single and multiple cancer diagnoses in a large population-based study.
Design, Setting, And Participants: In this genetic association study, whole-exome sequencing data were used from the UK Biobank, a UK population-based cohort that enrolled participants aged 40 to 69 years between 2006 and 2010.
Unusual Profile of Germline Genetic Variants in Unselected Colorectal Cancer Patients from a High-Prevalence Region in Panama.
Genes (Basel)
July 2025
Unidad de Genética y Salud Pública, Instituto de Ciencias Médicas, Las Tablas 0710, Panama.
Background: The profile of germline genetic variants among colorectal cancer patients in Panama has not yet been explored.
Methods: We recruited 95 patients with colorectal cancer in an Oncology Reference Hospital Unit in the Azuero region of central Panama, which exhibited the highest prevalence of colorectal cancer in Panama. DNA analysis was performed with a panel of 113 genes with germline mutations for cancer (TruSight Cancer Sequencing Panel from Illumina, San Diego, CA, USA).
Prevalence of Incidental Breast Cancer and Precursor Lesions in Carriers of Pathogenic Germline Variants Undergoing Risk-Reducing Mastectomy.
Anticancer Res
September 2025
HBOC-Center, Department of Gynecology with Breast Center, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Berlin, Germany.
Background/aim: Precursor lesions, including B3 lesions of uncertain malignant potential, preinvasive lesions such as ductal carcinoma (DCIS), and invasive lesions identified in the breast tissue of carriers of pathogenic germline variants undergoing risk-reducing breast surgery, have received limited attention to date. This study aimed to assess the prevalence and histopathological features of these lesions, considering their genetic, demographic, and radiological characteristics.
Patients And Methods: We performed a retrospective monocentric cohort study analyzing 169 healthy women and patients after previous breast cancer who carried pathogenic germline variants in , and .